Shares of Teladoc Health Inc. (TDOC) plummeted 5.07% in Monday's pre-market trading session, as concerns over the company's growth and profitability prospects weighed on investor sentiment.
A recent analysis highlighted several red flags for Teladoc's business:
While Teladoc's current valuation at 4.6x forward EV-to-EBITDA (or $9.38 per share) appears reasonable, the company's shakier fundamentals and potential growth challenges present downside risks for investors. As a result, analysts recommend caution when considering investing in Teladoc and suggest exploring more promising opportunities in the market.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。